Author

Sakina Hoosen

Institution: Novartis (United States)

Observed institutions: University of Iowa, Mayo Clinic, The University of Texas MD Anderson Cancer Center, Pfizer (United States), Institut Gustave Roussy, Moffitt Cancer Center, University of Alabama at Birmingham, Hospices Civils de Lyon, Dana-Farber Cancer Institute, Novartis (United States), The Ohio State University, University of KwaZulu-Natal

OpenAlex ID: A5111908411

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

2011 · James C. Yao, Manisha H. Shah, et al. · New England Journal of Medicine · 2,882

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

2009 · James C. Yao, Catherine Lombard-Bohas, et al. · Journal of Clinical Oncology · 649

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

2011 · James C. Yao, Marianne Pavel, et al. · The Journal of Clinical Endocrinology & Metabolism · 225

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

2006 · Robert J Motzer, Sakina Hoosen, et al. · Expert Opinion on Investigational Drugs · 118

A Study of Urinary Sodium and Potassium Excretion Rates Among Urban and Rural Zulus and Indians

1985 · Sakina Hoosen, Yackoob K. Seedat, et al. · Journal of Hypertension · 27

A study of urinary and intracellular sodium and potassium, renin, aldosterone, and hypertension in blacks and indians in natal

1990 · Sakina Hoosen, Y. K. Seedat, et al. · Cardiovascular Drugs and Therapy · 10

Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy

2010 · James C. Yao, Catherine Lombard-Bohas, et al. · Pancreas · 2

Sunitinib and Renal Cell Carcinoma

2007 · Sakina Hoosen, Robert Motzer · CRC Press eBooks

Works count: 9

Citation count: 3,913

H-index: 6

I10-index: 6